Govoni M, Neri S, Labella T, Sylvester J E, Novello F, Pession A
Istituto di Biochimica delle Proteine ed Enzimologia, CNR, Napoli, Italy.
Biochem Biophys Res Commun. 1995 Aug 4;213(1):282-8. doi: 10.1006/bbrc.1995.2127.
The interaction of topoisomerase II (topo II) with human ribosomal DNA (rDNA) was investigated in vivo using the antitumoral drug VM26, a specific inhibitor of topo II, that stabilizes the transient cleavable complex. rDNA-protein complexes isolated from nucleoli of TG cells were analyzed for double strand breaks with probes that covered almost all intergenic transcribed spacer (IGS) and all transcribed sequences of tandem repeat ribosomal DNA genes. Preferential cleavage sites were present in only a part of nucleolar rDNA, i.e., the transcribed region. Proteins, purified from the same complexes, were analyzed by Western-blot and stained by an antiserum against both topo II forms, showing the presence of topo II beta.
使用拓扑异构酶II(topo II)的特异性抑制剂、抗肿瘤药物VM26在体内研究了topo II与人核糖体DNA(rDNA)的相互作用,VM26可稳定瞬时可裂解复合物。用覆盖几乎所有基因间转录间隔区(IGS)和串联重复核糖体DNA基因所有转录序列的探针分析从TG细胞的核仁中分离出的rDNA-蛋白质复合物的双链断裂情况。仅在核仁rDNA的一部分即转录区域中存在优先切割位点。通过蛋白质印迹分析从相同复合物中纯化的蛋白质,并用针对两种topo II形式的抗血清染色,结果显示存在topo IIβ。